Thursday, June 18, 2009
THURSDAY, June 18 (HealthDay News) -- A panel of tests for multiple protein biomarkers of ovarian cancer, including CA-125, may be able to reliably detect the disease earlier than testing for CA-125 alone, according to a study reported in the June issue of the American Journal of Obstetrics & Gynecology.
Vladimir Nosov, M.D., of the University California Los Angeles Medical Center, and colleagues tested 358 serum samples from the National Cancer Institute that came from women with early- and late-stage ovarian cancer, women with benign adnexal masses, and a disease-free control group. The serum was tested for CA-125 and for three additional protein candidates for ovarian cancer detection: apolipoprotein A-1, transthyretin, and transferrin. The sensitivity and specificity of the protein panel was calculated using multiple logistic regression.
The researchers found that the panel of three proteins combined with CA-125 detected ovarian cancer at an early stage with a sensitivity of 96 percent. For the endometrioid subtype of early-stage disease, the sensitivity increased to 98 percent.
"A panel of four serum biomarkers effectively detected early-stage ovarian cancers with the highest reported overall sensitivity of 96 percent. Endometrioid tumors were detected at early stages with a sensitivity of 98 percent. Prospective clinical analysis of the panel is needed to validate it as an effective screening tool for early-stage ovarian cancer," the authors write.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.